Glaukos Corporation Stock News

U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday. The Dow traded up 1.45% to 31,596.87 while the NASDAQ rose 1.99% to 11,774.77. The S&P 50

Investors were cheered by the latest update from the lab.

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. Quoin Phar

Glaukos Corporation (NYSE: GKOS) gained 17.3% to $56.40 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary effica

Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieve

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.

Glaukos (GKOS) delivered earnings and revenue surprises of -88.64% and 7.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Corporation (NYSE:GKOS ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - P

McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.

Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.